IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.468
EU - Europa 9.221
NA - Nord America 7.177
SA - Sud America 2.562
AF - Africa 199
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 6
Totale 28.657
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.822
RU - Federazione Russa 4.836
SG - Singapore 3.266
CN - Cina 2.873
BR - Brasile 2.092
IT - Italia 1.512
HK - Hong Kong 1.400
SE - Svezia 1.040
VN - Vietnam 845
FR - Francia 476
BD - Bangladesh 418
DE - Germania 371
AR - Argentina 199
GB - Regno Unito 193
FI - Finlandia 165
IN - India 151
CA - Canada 148
NL - Olanda 141
MX - Messico 119
AT - Austria 118
EC - Ecuador 95
IE - Irlanda 74
ZA - Sudafrica 67
PL - Polonia 66
ID - Indonesia 63
IQ - Iraq 61
JP - Giappone 51
TR - Turchia 47
CO - Colombia 43
ES - Italia 43
PK - Pakistan 41
PY - Paraguay 40
AE - Emirati Arabi Uniti 32
MA - Marocco 31
MY - Malesia 31
UA - Ucraina 31
VE - Venezuela 28
SA - Arabia Saudita 24
KE - Kenya 23
CL - Cile 22
AU - Australia 21
CH - Svizzera 21
EG - Egitto 20
LT - Lituania 20
UZ - Uzbekistan 20
PE - Perù 19
TN - Tunisia 18
JM - Giamaica 16
AZ - Azerbaigian 14
UY - Uruguay 14
DK - Danimarca 13
MD - Moldavia 13
BE - Belgio 12
HN - Honduras 12
IL - Israele 12
NP - Nepal 12
PH - Filippine 12
CR - Costa Rica 11
BO - Bolivia 10
KZ - Kazakistan 10
DZ - Algeria 9
IR - Iran 9
GR - Grecia 8
KR - Corea 8
PT - Portogallo 8
TH - Thailandia 8
AL - Albania 7
DO - Repubblica Dominicana 7
JO - Giordania 7
KW - Kuwait 7
PA - Panama 7
SV - El Salvador 7
TW - Taiwan 7
BG - Bulgaria 6
BH - Bahrain 6
GT - Guatemala 6
HU - Ungheria 6
TT - Trinidad e Tobago 6
AO - Angola 5
CZ - Repubblica Ceca 5
NI - Nicaragua 5
NO - Norvegia 5
OM - Oman 5
RS - Serbia 5
SN - Senegal 5
BB - Barbados 4
BY - Bielorussia 4
ET - Etiopia 4
LB - Libano 4
LU - Lussemburgo 4
MV - Maldive 4
RO - Romania 4
CY - Cipro 3
GA - Gabon 3
GD - Grenada 3
KG - Kirghizistan 3
LV - Lettonia 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
Totale 28.614
Salva come PNG Salva come JPEG
Città #
Dallas 2.089
Singapore 1.425
Hong Kong 1.392
Moscow 1.154
Ashburn 842
San Jose 776
Shanghai 488
Hefei 435
Lauterbourg 382
Milan 354
Lawrence 328
Princeton 328
Ho Chi Minh City 310
Beijing 278
New York 251
Hanoi 179
São Paulo 170
Rome 156
Los Angeles 154
Nuremberg 143
Council Bluffs 117
Santa Clara 115
Helsinki 89
Munich 75
Dublin 72
Boardman 66
Rio de Janeiro 55
Warsaw 55
Brooklyn 51
Guangzhou 51
Orem 51
Vienna 50
Houston 44
Brasília 42
Mexico City 42
Naples 42
Tokyo 41
Belo Horizonte 39
Da Nang 39
Buffalo 38
Chennai 37
Hangzhou 37
Johannesburg 37
Lappeenranta 36
Montreal 36
Palermo 36
London 35
The Dalles 35
Curitiba 34
Denver 34
Turku 34
Chicago 33
Guayaquil 33
Xi'an 32
Stockholm 30
Haiphong 29
Porto Alegre 29
Atlanta 28
Frankfurt am Main 28
Poplar 28
Quito 26
Columbus 25
Phoenix 25
Seattle 25
Tianjin 25
Bari 24
Manchester 23
Turin 23
Amsterdam 22
Dubai 22
Nairobi 22
Shenzhen 22
Boston 21
Baghdad 20
Ribeirão Preto 20
Ridgewood 20
Salvador 20
Toronto 20
Hải Dương 19
Las Vegas 19
Mumbai 19
Tashkent 19
Thái Bình 19
Campinas 18
Manaus 18
Florence 17
Pune 17
Ankara 16
Bologna 16
Charlotte 16
Guarulhos 16
Washington 16
Changsha 15
Jakarta 15
Querétaro 15
San Francisco 15
Santiago 15
Santo André 15
Asunción 14
Biên Hòa 14
Totale 14.237
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 736
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 451
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 429
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 428
3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib 209
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) 200
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 192
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 147
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 144
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 141
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia 134
Chronic lymphocytic leukaemia 132
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 124
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 120
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 116
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 116
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 116
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 116
Supplementary Data from Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 114
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 113
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 111
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 110
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 109
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 108
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 108
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 108
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 106
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 106
A new life for rituximab? 105
A woman and her canary: a tale of chlamydiae and lymphomas 104
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 103
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 103
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study 103
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 102
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 100
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 100
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 99
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 98
Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience 98
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 98
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials 97
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 96
A frequent EcoRI polymorphism in the bcl-2 gene 96
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 95
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 95
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 94
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 94
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 94
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 93
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 93
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 92
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 92
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 92
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 91
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 91
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 90
Targeting B-cell anergy in chronic lymphocytic leukemia. 89
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 88
Monoclonal B-cell lymphocytosis: right track or red herring? 88
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 88
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 87
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 87
Chronic lymphocytic leukemia 87
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 87
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: Analysis within prospective clinical trials of the German CLL Study Group 87
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 87
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 87
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 86
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms 85
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 85
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee 84
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia 84
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 84
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA 84
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 83
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 83
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 82
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion 82
Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: A proof of concept for novel combination therapies 81
[Cellular and molecular mechanisms conditioning the accumulation of resting neoplastic cells in B-lymphocyte chronic lymphatic leukemia] 81
Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia 79
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x) 78
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 78
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 78
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 78
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results 77
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 77
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 77
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 77
Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients 77
TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics 76
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 75
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 75
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) 75
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL) 75
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity? 74
In vitro growth of human multiple myeloma: implications for biology and therapy 74
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 74
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 74
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results 74
Totale 11.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.903
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/20255.807 694 112 102 154 141 433 620 465 1.211 952 426 497
2025/202619.747 1.329 1.973 2.178 2.690 1.196 513 1.625 1.268 4.495 996 574 910
2026/2027301 301 0 0 0 0 0 0 0 0 0 0 0
Totale 29.197